Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
QLS5316 in advanced solid tumors
NCT07358884Phase 1Not yet recruiting
- Sponsor
- Qilu Pharmaceutical
- Start
- Jan 2026
- Primary completion
- Dec 2027
- Modality
- Bispecific Antibodies, Monoclonal Antibodies
01
Overview
Phase 1, open-label, single-arm trial of QLS5316 in solid tumor, colorectal cancer (CRC), gastric cancer (GC) and 3 more, sponsored by Qilu Pharmaceutical. Primary endpoints: Number of participants with adverse events, Number of Participants With Clinical Laboratory Test Abnormalities and 6 more. Planned start Jan 2026; status: not yet recruiting.
02
Drugs
QLS5316
03
Conditions
solid tumorcolorectal cancer (CRC)gastric cancer (GC)gastroesophageal junction adenocarcinomahead and neck squamous cell carcinoma (HNSCC)
Beyond the preview
Go deeper on NCT07358884.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07358884.